Given that a growing number of studies suggest that treatment intervention early in the process of the disease would provide better clinical benefits, we evaluated the impacts of GA immunomodulation in various stages of AD in APPswe/PSEN1dE9 (APP/PS1) transgenic mice, subcutaneously injected GA for 12 weeks at different time points (2- and 6-month-old), and, respectively, sacrificed the mice at 6 and 10 months of old (Figure 1). The gene discussed is PSEN1; the disease is Alzheimer disease.